English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Brentuximab vedotin (BV) is an antibody drug conjugate targeting the CD30 antigen. It employs a cleavable protease linking to a monomethyl auristatin E (MMAE) cytotoxic payload. It was 2011 when the first U.S. Food and Drug Administration (FDA) approvals occurred in relapsed/refractory Hodgkin lymphoma (HL) and relapsed/refractory CD30+ anaplastic large-cell lymphoma (ALCL). Single-agent response rates exceeded 75 percent in both settings. The next approval arrived in 2015 to be used as a single-agent maintenance strategy in high-risk HL post–autologous stem cell transplantation. In 2017 it was approved for use in relapsed cutaneous T-cell lymphoma and CD30+ mycosis fungoides. Then, in 2018, it was approved for use in frontline HL as part of the AAVD (adcetris, adriamycin, vinblastine, dacarbazine) regimen based on a modest progression-free survival (PFS) benefit when compared to ABVD (adriamycin, bleomycin, vinblastine, dacarbazine). The HL trial leading to approval was called ESCHELON-1.

Pulmonary Embolism Response Teams: Structuring a Dedicated Provider Response to Improve Outcomes for Patients and Institutions